Publications by authors named "P A O'Shea"
Aims/hypothesis: Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes because of suboptimal glucose management and glucose control and excessive weight gain. Metformin can offset these factors but is associated with small for gestational age (SGA) infants. We sought to identify risk factors for SGA infants, including the effect of metformin exposure on SGA status.
View Article and Find Full Text PDFProof-of-concept study: Remote capillary blood collection for hCG analysis in early pregnancy.
Eur J Obstet Gynecol Reprod Biol
September 2024
Introduction: Capillary blood collection, a technique traditionally used in diabetes care, shows promise for many applications including pregnancy monitoring. Serial measurement of serum human Chorionic Gonadotrophin (hCG) is frequently necessary for managing early pregnancy, including molar pregnancy, requiring multiple visits to a maternity hospital for blood collection by venepuncture. This proof-of-concept study aimed to assess the clinical performance and user acceptability of capillary blood samples collected remotely, as an alternative to venous blood for hCG measurement.
View Article and Find Full Text PDFAim: Women with GDM display adverse lifetime cardio-metabolic health. We examined whether early metformin in GDM could impact cardio-metabolic risk factors postpartum.
Research Design & Methods: EMERGE, a double-blind, placebo-controlled trial randomized pregnancies 1:1 to placebo or metformin at GDM diagnosis and followed participants from randomization until 12±4 weeks postpartum.
Dielectric materials are foundational to our modern-day communications, defense, and commerce needs. Although dielectric breakdown is a primary cause of failure of these systems, we do not fully understand this process. We analyzed the dielectric breakdown channel propagation dynamics of two distinct types of electrical trees.
View Article and Find Full Text PDFArticle Synopsis
- Targeting the estrogen receptor alpha (ERα) pathway is a proven strategy for treating estrogen receptor-positive (ER+) breast cancers, leading to the development of a new type of drug called a PROTAC designed to degrade ERα.
- In laboratory tests, this PROTAC showed strong effectiveness in degrading ERα and blocking its activity in breast cancer cells, but results did not match when tested in live models.
- The discrepancy is attributed to the PROTAC’s linker being metabolically unstable, which leads to the creation of competing metabolites that interfere with the drug's ability to degrade ERα; this emphasizes the importance of designing more stable PROTACs for better treatment outcomes.